Antidiabetic Potential of GlucoGuard, a Polyherbal Formulation in Type 2 Diabetes Management

Abstract

Type 2 diabetes mellitus (T2DM) affects over 500 million adults worldwide, yet current pharmacotherapies often provide only partial glycemic control and may cause adverse effects. Polyherbal formulations can offer complementary benefits through synergistic mechanisms and reduced toxicity. This study investigated the antidiabetic potential of GlucoGuard, a polyherbal aqueous extract containing Hunteria umbellata, Terminalia catappa, Zingiber officinale, and Beta vulgaris (3:1:1:1), in nicotinamide-streptozotocin-induced diabetic Wistar rats. Male rats (190–200 g) were randomly selected and divided into six groups (n = 6): normal control, diabetic control, three GlucoGuard-treated groups (100, 200, and 400 mg/kg), and a metformin-treated group (200 mg/kg). Acute toxicity testing showed no mortality or adverse effects up to 4,000 mg/kg. Oral treatment for 28 days significantly reduced fasting blood glucose in all GlucoGuard groups (p < 0.05), with the 200 and 400 mg/kg doses lowering levels to 92.1 ± 2.0 and 89.6 ± 1.8 mg/dL, comparable to metformin (90.3 ± 1.8 mg/dL). Higher doses also increased plasma insulin from diabetic baseline values, significantly mitigated weight loss, improved HbA1c, and ameliorated markers of renal function and protein metabolism towards normal levels. Hepatic enzyme assays revealed increased hexokinase activity and decreased glucose-6-phosphatase and fructose-1,6-bisphosphatase, indicating enhanced glycolysis and suppressed gluconeogenesis. These results suggest GlucoGuard provides dose-dependent, multi-mechanistic antidiabetic effects comparable to metformin, supporting its further evaluation as a safe, plant-based therapeutic candidate for T2DM.